

DEPARTMENT OF THE AIR FORCE 59TH MEDICAL WING (AETC) JOINT BASE SAN ANTONIO - LACKLAND TEXAS

2 FEB 2017

MEMORANDUM FOR SGCEE

ATTN: CAPT TIMOTHY A. SOEKEN

FROM: 59 MDW/SGVU

SUBJECT: Professional Presentation Approval

- Your paper, entitled <u>Sealing of Corneal Lacerations Using Photo-Activated Rose Bengal Dye and Amniotic Membrane</u> presented at/published to <u>Sun and Science</u>, <u>Galveston</u>, <u>TX 22 April 2017</u> in accordance with MDWI 41-108, has been approved and assigned local file #17040.
- 2. Pertinent biographic information (name of author(s), title, etc.) has been entered into our computer file. Please advise us (by phone or mail) that your presentation was given. At that time, we will need the date (month, day and year) along with the location of your presentation. It is important to update this information so that we can provide quality support for you, your department, and the Medical Center commander. This information is used to document the scholarly activities of our professional staff and students, which is an essential component of Wilford Hall Ambulatory Surgical Center (WHASC) internship and residency programs.
- 3. Please know that if you are a Graduate Health Sciences Education student and your department has told you they cannot fund your publication, the 59th Clinical Research Division may pay for your basic journal publishing charges (to include costs for tables and black and white photos). We cannot pay for reprints. If you are 59 MDW staff member, we can forward your request for funds to the designated wing POC.
- Congratulations, and thank you for your efforts and time. Your contributions are vital to the medical mission. We look forward to assisting you in your future publication/presentation efforts.

LINDA STEEL-GOODWIN, Col, USAF, BSC Director, Clinical Investigations & Research Support

hin da Steel-Goodwin

PROCESSING OF PROFESSIONAL MEDICAL RESEARCH/TECHNICAL PUBLICATIONS/PRESENTATIONS

INSTRUCTIONS

USE ONLY THE MOST CURRENT 59 MDW FORM 3039 LOCATED ON AF E-PUBLISHING

- 1. The author must complete page two of this form:
 - a. In Section 2, add the funding source for your study [e.g., 59 MDW CRD Graduate Health Sciences Education (GHSE) (SG5 O&M); SG5 R&D;
 Tri-Service Nursing Research Program (TSNRP); Defense Medical Research & Development Program (DMRDP); NIH; Congressionally Directed Medical Research Program (CDMRP); Grants; etc.]
 - b. In Section 2, there may be funding available for journal costs, if your department is not paying for figures, tables or photographs for your publication. Please state "YES" or "NO" in Section 2 of the form, if you need publication funding support.
- 2. Print your name, rank/grade, sign and date the form in the author's signature block or use an electronic signature.
- Attach a copy of the 59 MDW IRB or IACUC approval letter for the research related study. If this is a technical publication/presentation, state the type (e.g. case report, QA/QI study, program evaluation study, informational report/briefing, etc.) in the "Protocol Title" box.
- 4. Attach a copy of your abstract, paper, poster and other supporting documentation.
- Save and forward, via email, the processing form and all supporting documentation to your unit commander, program director or immediate supervisor for review/approval.
- 6. On page 2, have either your unit commander, program director or immediate supervisor:
 - a. Print their name, rank/grade, title; sign and date the form in the approving authority's signature block or use an electronic signature.
- 7. Submit your completed form and all supporting documentation to the CRD for processing (59crdpubspres@us.af.mil). This should be accomplished no later than 30 days before final clearance is required to publish/present your materials. If you have any questions or concerns, please contact the 59 CRD/Publications and Presentations Section at 292-7141 for assistance.
- The 59 CRD/Publications and Presentations Section will route the request form to clinical investigations, 502 ISG/JAC (Ethics Review) and Public Affairs
 (59 MDW/PA) for review and then forward you a final letter of approval or disapproval.
- Once your manuscript, poster or presentation has been approved for a one-time public release, you may proceed with your publication or presentation submission activities, as stated on this form. Note: For each new release of medical research or technical information as a publication/presentation, a new 59 MDW Form 3039 must be submitted for review and approval.
- 10. If your manuscript is accepted for scientific publication, please contact the 59 CRD/Publications and Presentations Section at 292-7141. This information is reported to the 59 MDW/CC. All medical research or technical information publications/presentations must be reported to the Defense Technical Information Center (DITC). See 59 MDWI 41-108, Presentation and Publication of Medical and Technical Papers, for additional information.
- 11. The Joint Ethics Regulation (JER) DoD 5500.07-R, Standards of Conduct, provides standards of ethical conduct for all DoD personnel and their interactions with other non-DoD entities, organizations, societies, conferences, etc. Part of the Form 3039 review and approval process includes a legal ethics review to address any potential conflicts related to DoD personnel participating in non-DoD sponsored conferences, professional meetings, publication/presentation disclosures to domestic and foreign audiences, DoD personnel accepting non-DoD contributions, awards, honoraria, gifts, etc. The specific circumstances for your presentation will determine whether a legal review is necessary. If you (as the author) or your supervisor check "NO" in block 17 of the Form 3039, your research or technical documents will not be forwarded to the 502 ISG/JAC legal office for an ethics review. To assist you in making this decision about whether to request a legal review, the following examples are provided as a guideline:

For presentations before professional societies and like organizations, the 59 MDW Public Affairs Office (PAO) will provide the needed review to ensure proper disclaimers are included and the subject matter of the presentation does not create any cause for DoD concern.

If the sponsor of a conference or meeting is a DoD entity, an ethics review of your presentation is not required, since the DoD entity is responsible to obtain all approvals for the event.

If the sponsor of a conference or meeting is a non-DoD commercial entity or an entity seeking to do business with the government, then your presentation should have an ethics review.

If your travel is being paid for (in whole or in part) by a non-Federal entity (someone other than the government), a legal ethics review is needed. These requests for legal review should come through the 59 MDW Gifts and Grants Office to 502 ISG/JAC.

If you are receiving an honorarium or payment for speaking, a legal ethics review is required.

If you (as the author) or your supervisor check "YES" in block 17 of the Form 3039, your research or technical documents will be forwarded simultaneously to the 502 ISG/JAC legal office and PAO for review to help reduce turn-around time. If you have any questions regarding legal reviews, please contact the legal office at (210) 671-5795/3365, DSN 473.

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement:

"The views expressed are those of the [author(s)] [presenter(s)] and do not reflect the official views or policy of the Department of Defense or its Components"

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving humans:

"The voluntary, fully informed consent of the subjects used in this research was obtained as required by 32 CFR 219 and DODI 3216.02_AFI 40-402."

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving animals, as required by AFMAN

"The experiments reported herein were conducted according to the principles set forth in the National Institute of Health Publication No. 80-23, Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act of 1966, as amended."

PROCESSING OF PROFESSI	ONAL MEDICAL RE	ESEARC	H/TECHNICAL	PUBLICATIO	NS/PRES	ENTATIONS
1. TO: CLINICAL RESEARCH 2. FROM: (Auth						PROTOCOL NUMBER:
Timothy A. So	eken, Capt, O-3, SGC	CEE		X YES □	NO A	-2009-03
PROTOCOL TITLE: (NOTE: For each new remust be submitted for remust be submitted.)		ch or techni	ical information as a	publication/preser	ntation, a nev	w 59 MDW Form 3039
Sealing of Corneal Lacerations Using Photo		gal Dye a	nd Amniotic Men	nbrane		
6. TITLE OF MATERIAL TO BE PUBLISHED OF	R PRESENTED:					
Sealing of Corneal Lacerations Using Photo	o-Activated Rose Beng	gal Dye a	nd Amniotic Men	ıbrane		
7. FUNDING RECEIVED FOR THIS STUDY?	YES NO FUND	OING SOUF	RCE:US Departme	ent of Defense c	ontracts W8	81XWH-09-2-0050 ar
8. DO YOU NEED FUNDING SUPPORT FOR P	PUBLICATION PURPOSE	ES: YE	ES NO			
9. IS THIS MATERIAL CLASSIFIED? YES	⊠ NO					
10. IS THIS MATERIAL SUBJECT TO ANY LEGAND DEVELOPMENT AGREEMENT (CRADA), YES NO NOTE: If the answer is YES	MATERIAL TRANSFER A	AGREEME Agreemen	NT (MTA), INTELLE	ECTUAL PROPER	TY RIGHTS	
11. MATERIAL IS FOR: DOMESTIC RELE			FOT ATTACHES	DV OF HATES	TO DE 51	N IOUED PRESENTE
CHECK APPROPRIATE BOX OR BOXES F 11a. PUBLICATION/JOURNAL (List inten		HIS REQU	EST, ATTACH COL	PY OF MATERIAL	TO BE PUE	BLISHED/PRESENTED.
11b. PUBLISHED ABSTRACT (List intend	ded journal.)					
□ 11c. POSTER (To be demonstrated at me Sun and Science, Galveston, Texas, A		city, state,	and date of meeting	.)		
11d. PLATFORM PRESENTATION (At ci		of meeting,	state, and date of m	eting.)		
Sun and Science, Galveston, Texas, A	****					
11e. OTHER (Describe: name of meeting	, city, state, and date of m	meeting.)				
12. HAVE YOUR ATTACHED RESEARCH/TEC	HNICAL MATERIALS BE	EEN PREV	IOUSLY APPROVE	D TO BE PUBLIS	HED/PRESE	NTED?
YES NO ASSIGNED FILE #		DATE				
13. EXPECTED DATE WHEN YOU WILL NEED NOTE: All publications/presentations are re					ON TO DTIC	
DATE						
December 16, 2016						
14. 59 MDW PRIMARY POINT OF CONTACT	(Last Name, First Name,	M.I., email)		15. DUTY	PHONE/PAGER NUMBER
Timothy A. Soeken, timothy.a.soeken.mil(@mail.mil				594-1364	
16. AUTHORSHIP AND CO-AUTHOR(S) List i	n the order they will appe					
LAST NAME, FIRST NAME AND M.I.	GRADE/RANK	SQU	ADRON/GROUP/OF	FFICE SYMBOL	INSTI	TUTION (If not 59 MDW)
a. Primary/Corresponding Author	O-3	50TPS/	59MDSG/SGCEE	2		
Timothy A. Soeken	n/a	n/a	39MD3G/3GCEI		Massa	chusetts General Hosp
b. Hong Zhu	O-4		/59MDOG/SGCE	F	Massa	enderta General 1105]+
c. Brett W. Davies		0.2.00	SAMDOU/SUCE	L	Macca	chusetts General Hosp
d. Irene E. Kochevar	n/a	n/a				
e. Anthony J. Johnson	retired O-6	Army			BAMO	C, Ophthalmology
17. IS A 502 ISG/JAC ETHICS REVIEW REQU			YES NO	DEODMED IN CT	NOT ACCO	DANCE WITH 33 CED
I CERTIFY ANY HUMAN OR ANIMAL RESEAR 219, AFMAN 40-401_IP, AND 59 MDWI 41-108 ACCURATE MANUSCRIPT FOR PUBLICATIO	. I HAVE READ THE FIN	NAL VERSI	ION OF THE ATTAC	CHED MATERIAL	AND CERTI	FY THAT IT IS AN
18. AUTHOR'S PRINTED NAME, RANK, GRAI Timothy A. Soeken/Capt/O-3	DE		. AUTHOR'S SIGNA EKEN.TIMOTHY ADAM 1266500		5	20. DATE December 05, 2016
21. APPROVING AUTHORITY'S PRINTED NA Walter A. Steigleman, MD/CDR/Program			. APPROVING AUT			23. DATE December 07, 2016

		ESEAF	RCH/TECHNICAL PUBLICATIONS/PRE	SENTATIONS		
1st ENDORSEMENT (59 MDW/SGVU Use O						
TO: Clinical Research Division	24. DATE RECEIVED		25. ASSIGNED PROCESSING REQUEST FILE NUMBER			
59 MDW/CRD Contact 292-7141 for email instructions.	January 24, 2017		17040			
26. DATE REVIEWED		2	27. DATE FORWARDED TO 502 ISG/JAC			
28. AUTHOR CONTACTED FOR RECOMME	ENDED OR NECESSARY (CHANGE	S: NO YES If yes, give date.	□ N/A		
29. COMMENTS 🔀 APPROVED 🔲 DIS	SAPPROVED					
30. PRINTED NAME, RANK/GRADE, TITLE	OF REVIEWER	3	1. REVIEWER SIGNATURE	32. DATE		
Linda D Harris, GS-14, Chief, Ops Bran		100	HARRIS LINDA DAWN 113189058 Openin spread by York RIS LINDA (DAWN 1113189058) Openin RIS (LINDA (DAWN 11140006) Openin RIS (LINDA (DAWN 11140006) Openin RIS (LINDA (DAWN 11140006)) Openin RIS (LINDA (DAWN 1114006)) Openin RIS (LINDA (DAWN 11140	January 30, 2017		
	PORT	.0	merekadense (anche (anches i 19 kantane) Daler 2017 DT SELST (E.De. 1979)	January 30, 2017		
2nd ENDORSEMENT (502 ISG/JAC Use On	y)					
33. DATE RECEIVED		3	34. DATE FORWARDED TO 59 MDW/PA			
				Lee DATE		
36. PRINTED NAME, RANK/GRADE, TITLE	OF REVIEWER	3	7. REVIEWER SIGNATURE	38. DATE		
3rd ENDORSEMENT (59 MDW/PA Use Only	()					
39. DATE RECEIVED			40. DATE FORWARDED TO 59 MDW/SGVU			
January 30, 2017			January 30, 2017			
41. COMMENTS APPROVED (In con	pliance with security and po	olicy revie	ew directives.) DISAPPROVED			
42. PRINTED NAME, RANK/GRADE, TITLE	OF REVIEWER	- 1	43. REVIEWER SIGNATURE	44. DATE		
Kevin Iinuma, SSgt/E-5, 59 MDW Pub			INUMA KEVIN MITSUGU 1296227 Operate to primate Nation of Residual (2002/09) Operate to primate National (2002/09) Operate to primate National (2002/09) Operate to the St. Scienment (2004) Operate to the St. Sci	January 30, 2017		
4th ENDORSEMENT (59 MDW/SGVU Use	Only)					
45. DATE RECEIVED	46		R AUTHOR NOTIFIED BY PHONE OF APPROVAL	OR DISAPPROVAL EFT MESSAGE		
47. COMMENTS APPROVED D	SAPPROVED					
48. PRINTED NAME, RANK/GRADE, TITLE	: OF REVIEWER		49. REVIEWER SIGNATURE	50. DATE		



DEPARTMENT OF THE AIR FORCE 59TH MEDICAL WING (AETC) JOINT BASE SAN ANTONIO - LACKLAND TEXAS

8 DEC 2016

MEMORANDUM FOR SGCEE

ATTN: CAPT TIMOTHY A SOEKEN

FROM: 59 MDW/SGVU

SUBJECT: Professional Presentation Approval

- Your paper, entitled <u>Sealing of Corneal Lacerations Using Photo-Activated Rose Bengal Dye and Amniotic Membrane presented at/published to Military Refractive Surgery Safety and Standards Symposium, 10-12 January 2017</u> in accordance with MDWI 41-108, has been approved and assigned local file #17011.
- 2. Pertinent biographic information (name of author(s), title, etc.) has been entered into our computer file. Please advise us (by phone or mail) that your presentation was given. At that time, we will need the date (month, day and year) along with the location of your presentation. It is important to update this information so that we can provide quality support for you, your department, and the Medical Center commander. This information is used to document the scholarly activities of our professional staff and students, which is an essential component of Wilford Hall Ambulatory Surgical Center (WHASC) internship and residency programs.
- 3. Please know that if you are a Graduate Health Sciences Education student and your department has told you they cannot fund your publication, the 59th Clinical Research Division may pay for your basic journal publishing charges (to include costs for tables and black and white photos). We cannot pay for reprints. If you are 59 MDW staff member, we can forward your request for funds to the designated wing POC.
- Congratulations, and thank you for your efforts and time. Your contributions are vital to the medical mission. We look forward to assisting you in your future publication/presentation efforts.

PAUL T. BARNICOTT, GS-15-DAF

Deputy Director, Clinical Research Division

PROCESSING OF PROFESSIONAL MEDICAL RESEARCH/TECHNICAL PUBLICATIONS/PRESENTATIONS

INSTRUCTIONS

- 1. The author must complete page two of the 59 MDW Form 3039 (this form).
 - a) In Section 2, add the funding source for your study [e.g., 59 MDW CRD Graduate Health Sciences Education (GHSC) [SG5 O&M], SG5 R&D; Tri-Service Nursing Research Program (TSNRP); Defense Medical Research & Development Program (DMRDP); NIH; Congressionally Directed Medical Research Program (CDMRP); Grants; etc.]
- 2. Print your name, rank/grade, sign and date the form in the author's signature block or use electronic signature.
- Attach a copy of the 59th MDW IRB or IACUC approval letter for the research related study. If this is a technical publication/ presentation, state the type (e.g., case report, QA/QI study, program evaluation study, informational report/briefing, etc.) in the "Protocol Title" box of the 59 MDW Form 3039.
- 4. Attach a copy of your abstract, paper, poster and other supporting documentation.
- 5. Save and forward, via email, the processing form and all supporting documentation to your Unit Commander, Program Director or immediate supervisor for review/approval.
- 6. On page 2, have either your Unit Commander, Program Director or immediate supervisor
 - a) Print their name, rank/grade/title, sign and date the form in the approving authority's signature block or use electronic signature.
- 7. Contact the 59th CRD/Publications and Presentations Section at (292-7141) for instructions for submitting the request form.
- The 59th CRD/Publications and Presentations Section will route the request form to clinical investigations and public affairs and forward you a final letter of approval.
- Once your manuscript, poster or presentation has been approved for a one-time public release, you may proceed with your
 publication or presentation submission activities, as stated on the 59 MDW Form 3039. [NOTE: For each new release of
 medical research or technical information as a publication/presentation, a new 59 MDW Form 3039 must be submitted for
 review and approval.]
- 10. If your manuscript is accepted for scientific publication, please contact the 59th CRD/Publications and Presentations Section (292-7141). This information is reported to the 59 MDW/CC. All medical research or technical information publications/ presentations must be reported to the Defense Technical Information Center (DTIC). See 59 MDWI 41-108. Presentation and Publication of Medical and Technical Papers for additional information.

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement

"The views expressed are those of the [author(s)] [presenter(s)] and do not reflect the official views or policy of the Department of Defense or its Components."

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving humans:

"The voluntary, fully informed consent of the subjects used in this research was obtained as required by 32 CFR 219 and DoDI 3216.02_AFI 40-402, Protection of Human Subjects in Biomedical and Behavioral Research."

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving animals, as required by AFMAN 40-401_IP, The Care and Use of Laboratory Animals in DoD Programs:

"The experiments reported herein were conducted according to the principles set forth in the National Institute of Health Publication No. 80-23, Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act of 1966, as amended."

PROCESSING OF PROFE	SSIONAL MEDICAL	RESEARCH/TECHNICAL P	UBLICATIONS/PRE	SENTATIONS	
TO: Clinical Research Division/SGVU (59 MDW/SGVU)	Timothy A. Soeken, Capt.	AND TO THE CONTROL OF THE PERSON OF THE PERS	PROTOCOL NUMB A-2009-03	>377.11 1	
PROTOCOL TITLE - [NOTE: For each Form 3039 must be submitted for re Sealing of Corneal Lacerations Using F	view and approval.]		as a publication/presen	ntation, a new 59 MDW	
TITLE OF MATERIAL TO BE PUB Sealing of Corneal Lacerations Using F		al Dye and Amniotic Membrane			
2. FUNDING RECEIVED FOR THIS S	STUDY? XES NO	FUNDING SOURCE: US Dep	artment of Defense contra	acts W81XWH-09-2-00	
3. IS THIS MATERIAL CLASSIFIED? 4. IS THIS MATERIAL SUBJECT TO RESEARCH AND DEVELOPMEN' RIGHTS AGREEMENT ETC.? [NOTE: If the answer is "YES" the subject of	ANY LEGAL RESTRICTION TAGREEMENT (CRADA), YES NO en attach a copy to the Ag	MATERIAL TRANSFER AGREEM reement to the Publications/Pres	ENT (MTA), INTELLECT	UAL PROPERTY	
(ATTACH COPY OF MATERIAL T			OMESTIC RELEASE	FOREIGN RELEASE	
PUBLICATION/JOURNAL	(List intended publication/	journal)			
PUBLICATION ABSTRACT	Γ (List intended journal.)				
POSTER (To be demonstra	ated at meeting/Name of N	leeting, City, State, and Date of M	Meeting)		
PLATFORM PRESENTATION Military Refractive Surgery S	ON (At civilian institutions Safety and Standards Symp	/Name of Meeting, State, Date of osium. January 10-12, 2017	Meeting)		
OTHER (Describe: Name of	of Meeting, City, State, and	Date of Meeting)			
6. WHAT IS THE EXPECTED DATE DEFENSE TECHNICAL INFORM		PUBLICATION WILL BE SUBMITT	ED TO THE		
DEFENSE FECHNICAL INFORM		OINT OF CONTACT			
7. WHO IS THE PRIMARY 59 MDW Soeken, Timothy A timothy a soeken.mil@mail.mil	POINT OF CONTACT? (L	ast, First, Ml.) (Include email)	DUTY PE 210-594-	HONE/PAGER No. 1364	
AUTHOR	SHIP AND CO-AUTHOR(S	(List in the order they will appe	ar in the manuscript)	UTION (If not 59 MDW)	
a. Primary/corresponding author	O MI. GRADE/RAN	K SQUADRON/GROUP/OF	FFICE STM INSTITU	D HON (II HOL 55 MOVV)	
Timothy A. Soeken	0-3	59TRS/59MDSG/SGCEE	59MDW		
b. Hong Zhu	n/a	n/a	Massach	nusetts General Hospital	
c Sheri DeMartelaere	O-6	Army	BAMC.	BAMC. Ophthalmology	
d Brett W. Davies	0.4	59SGC/59MDOG/SGCEE	59MDW		
e. Rose Grimm	0-4	Army	usa isr		
f Irene E. Kochevar n/a		n/a	Massaci	husetts General Hospital	
g. Anthony J. Johnson	retired O-6	Army		Ophthalmology	
I CERTIFY ANY HUMAN OR ANIMAL RE 40-401_IP AND 59 MDWI 41-108. I HAVE FOR PUBLICATION AND/OR PRESENTA	E READ THE FINAL VERSION	WERE APPROVED AND PERFORME OF THE ATTACHED MATERIAL AND	D IN STRICT ACCORDANCE CERTIFY THAT IT IS AN AC	WITH 32 CFR 219, AFMAN CURATE MANUSCRIPT	
AUTHOR'S PRINTED NAME/RANK		AUTHOR'S SIGNATURE		DATE	
Timothy A. Soeken/Capt/O-3		SOEKEN TIMOTHY. ADAM. 1266509	programa for SCREEN TRACTUM RESIDENCE CONTRACTOR Contractor Contractor Contractor Contractor Contractor Contrac	Nov 8, 2016	
APPROVING AUTHORITY'S PRINT	TED NAME, RANK, TITLE	APPROVING AUTHORITY'S SIG		DATE	
Walter A. Steigleman, MD/CDR/Prog	gram Director	STEIGLEMAN.WALTER A.11859301	The second comment of the second of the seco	Nov 15, 2016	

PROCESSING OF PROFESSION	NAL MEDICA	L RESE	ARCH/TEC	HNIC	CAL PUBLICATIONS/PRE	SENTATIONS		
	1st INC	ORSEMEN	IT (SGVU Use	Only)			
TO: Clinical Research Division (59 MDW/SGVU) (Contact 292-7141 for email instructions)	1. DATE REC Nov 15, 2016		2. ASSIGNED PROCESSING REQUEST FILE NUMBER 17011					
3. DATE REVIEWED			4. DATE FO	RWA	RDED TO PA			
5. AUTHOR CONTACTED FOR RECOMMEN	DED OR NECES	SSARY CH	ANGES					
☐ NO ☐ YES If yes give of	tate: 15 Nov	16		N/A				
6. COMMENTS								
APPROVED DISAPPROVED								
				SICK	ATURE OF REVIEWER			
PRINTED NAME, RANK/GRADE, TITLE OF F Linda D Harris, GS 14, Chief, Ops Br	REVIEWER	DATE 17 Nov 1	6					
Linda D Harris, GS 14, Chier, Ops Bi	2nd I		ENT (PA Use	0	Tune 2014 111	SACIANALITE ERMAN FOR ENERGY OF SC		
TO: 59 MDW OFFICE OF PUBLIC AFFAIRS (PA)	1. DATE REC Dec 6, 2016	EIVED		RWA	RDED TO 59 MDW/SGVU			
		la.re		eici	NATURE OF REVIEWER			
PRINTED NAME, RANK/GRADE, TITLE OF I		DATE 2	216		IMA KEVIN MITSHGILL	ed by ENLINA KINDS MITHURAL CONSTRUCTION I		
Kevin linuma, SSgt/E-5, 59 MDW Public	Affairs	Dec 8, 20	016	296	227612 IN-MA	(EVIN MITSUGU 129632761) 3 pa 06 00:29 - 06 00		
	3rd IN	DORSEME	NT (SGVU Us	e Onl	y) 1. DATE RECEIVED			
TO: 59 MDW/SGVU								
2. SENIOR AUTHOR NOTIFIED BY PHONE	OF APPROVA	L OR DISA	PPROVAL:	YE	S NO Could not be read	hed Left message		
3. DATE WRITTEN NOTICE OF APPROVAL	AND CLEARA	NCE MAIL	ED TO AUTHO	OR:				
4. COMMENTS APPROVED D	SAPPROVED							
1								
PRINTED NAME, RANK/GRADE, TITLE OF	REVIEWER	SIGNAT	URE OF REVI	EWE	R	DATE		

**			

Sealing of Corneal Lacerations Using Photo-Activated Rose Bengal Dye and Amniotic
Membrane
Timothy A Soeken ¹ , Hong Zhu ² , Sheri DeMartelaere ³ , Brett W. Davies ¹ , Rose Grimm ⁴ , Irene E
Kochevar ² , Anthony J Johnson ^{1,4}
1 San Antonio Uniformed Services Health Education Consortium, San Antonio, TX
2. Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA
3. Landstuhl Regional Medical Center, Landstuhl, Rhineland-Palatinate, Deutschland
4. United States Army Institute of Surgical Research, Fort Sam Houston, TX
Corresponding Author:
Timothy A. Soeken MD
3551 Roger Brooke Drive, ATTN: Ophthalmology, JBSA Ft Sam Houston, TX 78234
(210) 916-4519
Conflict of Interest: None of the authors have a conflict of interest to declare.
Keywords: Amniotic Membrane, Photo-Activated Rose Bengal Dye, Corneal Laceration
Funding Organizations: US Department of Defense contracts W81XWH-09-2-0050 and FA9550-10-1-0537

21 Purpose: Watertight closure of perforating corneoscleral lacerations is necessary to prevent 22 epithelial ingrowth, infection, and potential loss of the eye. Complex lacerations can be difficult 23 to treat, and repair with sutures alone is often inadequate. In this study we evaluated a sutureless technology for sealing complex corneal and scleral lacerations that bonds amniotic membrane 24 (AM) to the wound using only green light and the dye, rose bengal (RB). 25 Methods: AM was impregnated with RB, then sealed over lacerations using green light to bond 26 the AM to the de-epithelialized cornea surface. This process was compared to suture repair of 27 three laceration configurations in New Zealand White (NZW) rabbits in three arms of the study. 28 A fourth study arm assessed the side effect profile including viability of cells in the iris, damage 29 to the blood-retinal barrier, the retinal photoreceptors, retinal pigment epithelium (RPE) and 30 choriocapillaris in Dutch Belted (DB) rabbits. 31 **Results:** Analyses of the first three arms revealed no significant difference between the groups 32 regarding induced edema to the corneal stroma, induced stroma thickening, endothelial necrosis, 33 and inflammation. In the fourth arm, iris cells appeared unaffected and no evidence of 34 breakdown of the blood retina barrier was detected. Retina from greenlight laser treated eyes 35 showed normal RPE, intact outer segments and normal outer nuclear layer (ONL) thickness. 36 Conclusions: The results of these studies established that a light-activated method to crosslink 37 AM to the cornea can be used for sealing complex penetrating wounds in the cornea and sclera 38 with minimal inflammation, or secondary effects. 39 40 The views expressed are those of the authors and do not reflect the official views or policy of the 41

Department of Defense or its Components.

- 43 The experiments reported herein were conducted according to the priniciples set forth in the
- National Institute of Health Publication No. 80-23, Guide for the Care and Use of Laboratory
- 45 Animals and the Welfare Act of 1966, as amended.

Introduction

- 48 Penetrating injury to the eye is a frequent ophthalmic emergency at trauma centers worldwide.
- 49 From the standpoint of the military ophthalmologist, fragments and debris propelled at high
- 50 velocity by improvised explosive devices (IEDs) have increased the incidence of penetrating eye
- 51 injuries compared to conflicts prior to the development of IEDs. At the height of the recent
- 52 conflict in Iraq, 29% of all evacuations from Iraq were due to ocular injuries (Joint Theater
- 53 Trauma Report, 2012)
- When an eye sustains a penetrating or perforating injury, rapid closure with the formation of a
- 55 water-tight seal is critical to preventing infection and preventing surface epithelium from gaining
- 56 entry into the eye. This stabilizes the eye until further reconstructive surgery can occur. Despite
- 57 the small surface area of the eye, repair of complex injuries can be labor and time intensive.
- 58 Effective repair of these injuries requires the use of specialized instruments and advanced
- 59 surgical training.
- 60 In complex lacerations in which flat objects are propelled through the cornea, the lamella of the
- 61 cornea can shred, making closure by suture impossible. In these cases surgical adjuncts are used
- to close the wound, none of which are currently approved by the FDA for this purpose.
- 63 Cyanoacrylate glue is the most commonly used adjunct, effectively binding to the cornea and
- 64 sealing the wound. While effective, there are a number of disadvantages to the use of this glue.
- These include difficulty in removal, adhesion to the sutures, and the opacity it creates. Thus, the
- 66 overall goal of this research was to find a more efficient method of sealing complex corneal
- 67 lacerations.
- To achieve this goal, we utilized a light-activated technology in which amniotic membrane (AM)

- 69 impregnated with rose bengal (RB) dye is cross-linked to the surface of the cornea. RB is a
- 70 common FDA-approved photoactive vital dye used as a diagnostic tool for staining ocular
- 71 surface abnormalities. Since it uses currently FDA approved materials/devices (clinical laser,
- 72 RB, AM) this method may be integrated rapidly to the modern civilian and deployed
- 73 environment with materials already in the ophthalmic surgical set.

Methods

This study utilized two separate groups of rabbits. For the treatment arms, 98 New Zealand White (NZW) rabbits were acquired. These rabbits were used to perform the surgical procedures and to record the clinical and histopathological data, all of which were completed at the United States Army Institute of Surgical Research (USAISR), San Antonio, TX. To evaluate the side effect profile of the procedure, 17 young female Dutch Belted (DB) rabbits were acquired. These rabbits were supplied by Millbrook Labs (Amherst, MA), and all procedures were performed at Massachusetts General Hospital, Boston, MA. All experiments were humanely performed in accordance with the ARVO statement for the Use of Animals in Ophthalmic and Vision Research. The study protocols were approved by the USAISR Institutional Animal Care and Use Committee (IACUC) and the Subcommittee on Research Animal Care at Massachusetts General Hospital. Methods, Treatment Arms A summary of the methods can be found in Table 1. The 98 NZW rabbits of the treatment arms

A summary of the methods can be found in Table 1. The 98 NZW rabbits of the treatment arms were separated into three treatment arms. For every animal, only the right eye was operated on in accordance with IACUC guidelines. Each treatment arm was separated into two groups—one control group treated with sutures only and one study group treated with the AM technique. In the first arm, a 4 mm linear central corneal laceration in the visual axis was made. In the second arm, a V shaped laceration in the central cornea with two 3 mm legs in an equatorial triangle fashion was made. In the third arm, a 4 mm corneal-scleral laceration centered in the limbus was made. The RB and the human AM used in this study were prepared and attained as previously described (Verter et al, 2011). A prototype light delivery system was constructed to deliver diffuse retina-safe light levels while providing sufficient energy for sealing corneal wounds

(Verter et al, 2011). All studies employed a clinical laser that emits green light at 532 nm. The laser instrument is an IRIDEX OcLightTX Ophthalmic 532 nm Laser Diode. The set power was 400 mW, and the beam diameter was 13 mm with a beam area of 1.33 cm². Due to losses in the delivery system, the measured power was 360 mW. The irradiance at 2 cm from the exit point of the lens was 271 mW/cm². Laser power was measured with a Scientech model 365, SN: 6277 (head model 380101). The first arm included a total of 40 live NZW rabbits. The right eye of all rabbits received a simple 4 mm linear central corneal laceration. The rabbit was placed under anesthesia, then prepped and draped in the normal sterile fashion for eye surgery. A lid speculum was placed in the eye and centered under the operating microscope. A surgical ruler was used to measure the central 4 mm of the cornea and 2 dots were placed. A diamond knife was then used to make a central laceration between the dots, which resulted in a gaping wound and collapse of the anterior chamber. In the 19 rabbits that served as the control group, repair of their corneal wound was completed with interrupted 10-0 nylon sutures. In the 17 rabbits of the treatment group the epithelium in the center of the cornea was debrided, and viscoelastic was injected into the wound to protect the lens and deepen the chamber. One central 10-0 nylon suture was placed. Preprepared AM impregnated with RB was then centered on the wound. The amnion was gently stroked with a 27 gauge cannula until it dried sufficiently to adhere to the cornea. The microscope was moved, the laser hand piece was centered over the wound and the AM was irradiated. The laser was set to a 13 mm beam diameter and 271 mW/cm²was delivered to the AM surface for 250 seconds for a total fluence of 68 J/cm2. Afterwards the wound was tested for water-tightness with fluorescein staining, and a tonopen was used to ensure the eye was at physiologic pressure.

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

The second arm of the study included a total of 30 NZW rabbits. For this arm, a complex Vshaped laceration was made in the center of each cornea. Each leg of the "V" was approximately 3 mm in length. The control group consisted of 15 rabbits, each of which received closure of their corneal wound with 5 interrupted 10-0 nylon sutures. The treatment group also consisted of 15 rabbits. After the epithelium was debrided, a single 10-0 nylon suture was placed at the wound apex. The AM was then applied and irradiated as previously described. All wounds were tested for water-tightness with fluorescein staining, and a tonopen was used to ensure the eye was at physiologic pressure. The third arm of the study included 28 NZW rabbits. For this arm, a 3 clock hour peritomy was placed from 10 0'clock until 1 o'clock. A 4mm laceration centered on the limbus in the 11:30 meridian was made. The control group consisted of 15 rabbits, each of which received closure of their corneoscleral laceration with four interrupted nylon sutures (10-0 on the cornea, 9-0 at the limbus, and 8-0 on the sclera). The treatment group consisted of 13 rabbits. After the epithelium was debrided, a single 10-0 nylon suture was placed at the limbus. The AM was then applied and irradiated as previously described. All wounds were tested for water-tightness with fluorescein staining, and a tonopen was used to ensure the eye was at physiologic pressure. In the post-operative period, each animal in all treatment groups was further subdivided into necropsy times of 3, 7 and 28 days. This allowed for clinical and histopathologic evaluation at various postoperative stages. Following euthanasia, the treated globes were isolated and the AM was removed. The globes were fixed in Modified Davidson's solution for 24-48 hours and then transferred to 10% buffered neutral formalin. After fixation, each globe was transected sagitally, embedded in paraffin, sectioned at 5 µm, and stained with hematoxylin and eosin (H&E). Corneal sections were analyzed for mononuclear and polymorphonuclear inflammation,

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

vascularization of the stroma, stromal edema, endothelial necrosis, and regeneration of the corneal epithelium.

Histopathological analysis was performed using a five point grading system (0-4) for each of the above variables. A score of zero was assigned for no observable characteristics, one was scored for minimal observable characteristics, two for mild, three for moderate, and four for severe characteristics. Inflammation was quantified by counting inflammatory cells per high powered field.

The results were then analyzed utilizing a repeated measures mixed model ANOVA for time dependent analysis. If the effect of time or the time-treatment interaction were not significant, the data was pooled together and a one-way ANOVA or Wilcoxon's Test were performed. All p-values < 0.05 were deemed statistically significant. All statistical analysis was performed using JMP v10.0.

Methods Side Effect Arm

The fourth arm of the study included 17 DB rabbits. The right eye of each rabbit was subjected to a simple 3 mm linear central corneal laceration. The epithelium was mechanical scratched after adding 30% ethanol for 15 sec on the cornea, and then a 3 mm-long linear incision was made in the central cornea. Human AM in diameter previously stained with RB was then placed over the incision as previously described (Verter et al, 2011). The cornea was then exposed to green light at an irradiance of 0.25 W/cm² for a total of 6.6 min (100 J/cm²). Half way through the 6.6 min, an additional 30 sec addition of RB was re-applied, then irradiated for the second half of the 6.6 min. This is done because the first 3.3 min bleaches the pink color of the dye and sufficient dye present to absorb the green light for crosslinking.

A LaserScope Aura StarPulse Laser (San Jose, CA) with a 600-um optical fiber in diameter was used for eye safety evaluation. The power was measured with a power meter (NOVA; Ophir Optronics Ltd., North Andover, MA) before each use. An optical system was designed and built to focus a 12 mm laser beam on the cornea then expand the beam to impinge on a larger area of the retina to minimize potential light-initiated damage as previously described (Zhu et al, 2016). The cornea surface temperature was recorded during treatment using a non-contact precision infrared thermometer (Fluke 572, Fluke Corporation, Everett, WA). The left eye of each rabbit served as a control; it was also de-epithelialized but received no further treatment. For the change in temperature, the measurements were made on each treated eye. The temperature at the beginning of the irradiation (~32 °C) was compared to the mean temperature between 60 and 360 minutes irradiation. The lactate dehydrogenase-nitro blue tetrazolium (LDH-NBT) staining method was used to assess the activity of the thermally sensitive enzyme, LDH as an indication of iris cell viability 178 179 using a previously described method (Zhu et al, 2016). A blue formazan product indicates cell viability. No statistical analysis of the iris damage was done. The response was qualitative, 180 either blue formazan was observed or not. 181 The rabbits were sacrificed on day 1 or 28. Prior to euthanasia, fundus fluorescein angiography 182 (FFA) was performed on day 28 after treatment of DB rabbits (n = 4 / day). After anesthesia the 183 pupil was dilated with 2 drops of 1% tropicamide hydrochloride eye solution. A scanning laser 184 ophthalmoscope (SLO) (HRA2, Heidelberg Engineering, Heidelberg) was used. One milliliter of 185 10% fluorescein sterile solution (Alcon Inc., Fort Worth, TX) was injected into the marginal ear 186 vein, and images were recorded immediately after injection. No statistical analysis of the FFA 187 was done. The vessels were observed for breakdown or leakage from the blood vessels. 188

166

167

168

169

170

171

172

173

174

175

176

Following necropsy, the cornea, iris and retina were separated and fixed in 10% formalin for 24
hours at room temperature, then embedded in paraffin. Five-micron vertical cut sections were
stained with H&E and scanned using a digital slide scanner (NanoZoomer Digital Pathology
System, Hamamatsu, Photonics, Japan). The morphology of the corneas was observed by light
microscopy. Retina H&E sections were used for outer nuclear layer thickness measurements.
The thickness of the outer nuclear layer (ONL) from the optic disc was measured at 10 points
with 200- μm intervals in each section to obtain the average for each retina. ONL thickness data
were tested by a two-tailed unpaired Student t test.
Each histologic evaluation was carried out in a masked fashion

Results, Treatment Arms

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

220

For the first, second and third arms of this study, there was no statistically significant difference between the treatment groups and control groups in terms of induced edema to the corneal stroma, induced stroma thickening, endothelial necrosis, and inflammation. This held true for all post-operative periods. Even after pooling the time points together, differences between these histology values remained non-significant. Figure 1 shows the pooled mean plot demonstrating there is no significant difference comparing crosslinking and suture closure for induced edema to the corneal stroma, induced stroma thickening, endothelial necrosis, nor inflammation (Wilcoxon p-values were 0.11, 0.45, 0.30, and 0.59, respectively). In order to understand the healing response to the performed interventions, a 2-way repeated measures mixed model ANOVA was utilized to evaluate the effects of using laser versus suture at all the various time points. Additional analysis between laser closure and suture closure demonstrated no difference in neovascularization, endothelial necrosis, inflammation, edema or stromal thickening between the laser and suture techniques. Between suture repair and laser crosslinking repair for the same time points there were no statistical differences in any of the categories except epithelial hyperplasia. On day 3 there was more epithelial hyperplasia in the control group, but the changes were not persistent as time progressed and none of the animals scored over 1 on the 0-4 scale (p=0.05). On slit lamp evaluations, the sutured corneas remained clearer than the cross-linked corneas at the 3 and 7 day time points. At 28 days there were no significant differences. Of note, by 7 days all the corneas were sufficiently clear to see iris detail, sufficient to allow reconstructive surgery to be performed. 219

Results, Side Effects Arm

In the fourth arm, the temperature on the surface of cornea during the procedure at 0.25 W/cm² 221 222 in DB rabbits was measured. As shown in Figure 2, the temperature increased 8 degrees. 223 In order to assess damage to iris cells during the procedure, the LDH-NBT assay was used which 224 shows deposition of a blue formazan product if cells are viable. The positive control was 225 untreated DB rabbit iris, which showed blue deposits in cells near melanin (Figure 3). Iris tissue 226 harvested 1 and 28 days after treatment showed similar deposits of blue formazan product in the 227 cells adjacent to melanin granules as found in the positive control. 228 FA images of the retina around the optic disc were examined for signs of leakage indicating 229 breakdown of the blood retina barrier, which may result from laser-induced RPE or endothelial cell damage. FFA was performed on Day 28 after treatment in DB rabbit corneas (100 J/cm²; n = 230 4 / group). Retinal vessels in the region of the optic disc were visible including small diameter 231 232 vessels (Figure 4). On Day 28 after treatment, diffuse fluorescein fluorescence in the avascular regions of the fundus was not detected nor was there any appearance of fluorescein leakage from 233 234 the retinal vessels (Figure 4 B). Irreversible damage to the photoreceptors could be assessed by measuring the ONLthickness, 235 which decreases after photoreceptor cell death. No significant difference was found in ONL 236 thickness between retinae from treated and untreated eyes on either day 1 or day 28 (n = 6/ 237 group, p > 0.05, Figure 4C). 238

Discussion

240

241 On the basis of prior studies, our team designed this study to compare the sealing of a central 242 cornea laceration and a corneoscleral laceration sealed with crosslinked RB impregnated AM to 243 traditional suture closure. Specifically, RB, without the AM, activated with neodymium: YAG laser light at 532 nm has been shown to seal a simple corneal laceration and provide a long 244 duration seal (Proano et al, Invest 2004; Proano et al, J Cataract 2004). Later, it was 245 246 demonstrated that the technique used in this study sealed incisions in ex vivo rabbit eyes to withstand an intraocular pressure of 350 mm Hg, more than 10 times normal pressure (Verter et 247 al, 2011). 248 249 To determine the appropriate laser parameters for sealing the AM to the surface of the eye, we carried out pilot ex vivo studies. Over 1000 seconds exceeded the calculated safety threshold. 250 251 Successful cross-linking the AM was attained at 400 seconds, and at 250 seconds there was about 90% strength. Thus, we selected 250 seconds in this protocol, which correlated to a total 252 fluence of 68 J/cm2 when the laser was set to a 13mm beam diameter and 271 mW/cm2. The 253 combination of the 1000 second upper limit and the 250 second treatment would allow up to four 254 255 tries if the AM did not adhere to the ocular surface satisfactorily. In the model development stage for this study, we determined that due to gaping of the central 256 lacerations and the larger V shaped laceration, and brisk aqueous outflow, a direct closure with 257 AM was near impossible. This also put the patient at risk because the scar required to fill the gap 258 would decrease visual function, the AM over the gap would tectonically be too weak, and the 259 brisk outflow would also prevent adhesion of the AM to the cornea prior to crosslinking. This 260 was not evident in the abattoir eyes used in pilot studies and the previous study (Verter, 2011) 261 because there was no aqueous outflow and the low pressure did not cause wound gap. Thus the 262

technique was modified to place one suture in the wound to approximate the corneal stromal surfaces. This accomplished three things. It minimized the scar size, tectonically strengthened the cornea and allowed air or viscoelastic to block the outflow of aqueous sufficient to crosslink AM to the cornea. Previous studies indicate that RB demonstrated potential toxicity to cultured epithelial cells and that the use of AM in albino rabbits is associated with granulomatous inflammation (Tabery, 1998; Barton et al, 2001). As demonstrated in Figure 1, crosslinking AM to the cornea surface was no more damaging than suturing. This study also demonstrates histopathologically that the AM patched corneas did not cause any adverse reactions in the rabbits. The only statistically significant difference in the histopathological analysis of the three surgical arms was the epithelial hyperplasia noted on day 3. The authors hypothesize that this reflects the healing of the surface after scraping and neovascularization. None of the animals scored over one on the zero to four scale. The neovascularization noted was related to anterior chamber and iris changes that the rabbit developed while the anterior chamber was flat. On two rabbits the iris was stuck to the underside of the cornea on slit lamp evaluation. This is not an uncommon response and likewise occurs in humans when the iris comes in contact with cornea for a period of time and the iris is irritated or inflamed. This could contribute to gradual 279 loss of endothelial cells, and could prompt a return to the operating room in the future to remove 280 the iris if the adhesion was significant or evidence of endothelial failure was present. There 281 appeared to be no neovascularization responses to the cross-linking procedure in the wounds. 282 To evaluate potential deleterious effects of laser crosslinking, we analyzed the cornea surface 283 temperature, iris cellular damage, and retinal blood-retinal barrier and outer nuclear layer. None 284 of these measures indicated damage to these ocular structures resulting from the treatment. 285

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

Since photothermal damage on the cornea might occur due to absorption of the laser light, we measured the temperature on the surface of cornea during the procedure. As shown in Figure 2, the temperature increased less than 42°C, a temperature at which thermal damage is not expected (Landry and Marceau, 1978). In addition to the cornea, we also evaluated the thermal effects on the iris. High irradiances and fluences may heat the melanin particles in the iris and damage adjacent iris cells. Using the LDH-NBT staining method, an accepted method for detecting thermal damage in tissues (Sherwood and Flotte, 2007), our results indicated that iris cells near the melanin particles were still viable (Figure 3). These results demonstrate that the iris cells are not thermally damaged during treatment. We used two methods to assess potential side effects on the retinas of DB rabbits, namely, FFA and ONL thickness. Fluorescence images of the retina around the optic disc were examined for signs of fluorescein leakage indicating breakdown of the blood retina barrier resulting from laser-induced RPE or endothelial cell damage. FFA performed on Day 28 after treatment showed retinal vessels, including small diameter vessels, without diffuse fluorescein fluorescence in the avascular regions of the fundus or any appearance of fluorescein leakage from the retinal vessels (Figure 4B). These results suggest that the retinal radiant exposure was not sufficient to initiate thermal damage to either the RPE cells or to retinal vessels. Irreversible damage to the photoreceptors was assessed by measuring the outer nuclear layer thickness, which decreases after photoreceptor cell death. No significant difference was found in outer nuclear layer thickness between retinae from treated and untreated eyes either on Day 1 and Day 28 Figure 4 C). In conclusion, the results of these studies established that a light-activated method to crosslink AM to the cornea can be used for sealing complex penetrating wounds in the cornea, and the

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

sclera, with minimal inflammation, or secondary effects. We did not identify problems or obstacles that will inhibit the translation of this light-activated repair technique to clinical use. This treatment involves off-label use of three FDA-allowed materials/devices (clinical laser, RB, human AM), which may facilitate translation to the clinic. Rose bengal is approved as diagnostic agent but not as a treatment agent; thus further safety documentation would be beneficial. In all applications a strong seal was produced immediately. The best method for sealing corneal and scleral wounds is to bond AM over the wound using a dye and green laser light, after any significant gaps in the stroma have been reduced with sutures. Thus, for these experiments this technology appears to be best employed as an adjunct to only suturing to reduce operative time or when edges cannot be approximated in cases with brisk aqueous outflow, as occurs in simple lacerations.

		Side Effect Arm		
Location of Experimental	USA	MGH, Boston,		
Procedure		MA		
Rabbit Type	N	lew Zealand W	/hite	Dutch Belted
				Pigmented
Study Arm	1	2	3	4
Number of Rabbits	40	30	28	17
Experimental Wound	4mm	"V" shaped	4mm linear	3mm linear central
	linear	central	corneoscleral	cornea laceration
	central	cornea	laceration	
	cornea	laceration		
	laceration			
Number of Experimental	21	15	13	17
Eyes				
Repair Method	A single	A single	A single 10-0	Rose Bengal
	central 10-	10-0 nylon	nylon suture a	impregnated
	0 nylon	suture at	the limbus,	amniotic
	suture,	the "V"	and Rose	membrane
	and Rose	apex, and	Bengal	irradiated for 400
	Bengal	Rose	impregnated	seconds of a
	impregnat	Bengal	amniotic	12mm diameter
	ed	impregnate	membrane	400mW laser
	amniotic	d amniotic	irradiated for	

membrane	membrane	250 seconds of	
irradiated	irradiated	a 13mm	
for 250	for 250	diameter	
seconds of	seconds of	400mW laser	
a 13mm	a 13mm		
diameter	diameter		4
400mW	400mW		
laser	laser		
19	15	15	-
interrupte	interrupted	interrupted	-
d 10-0	10-0 nylon	nylon sutures:	
nylon	sutures	10-0 on	
sutures		cornea,	
		9-0 on limbus,	
		8-0 on sclera	
	irradiated for 250 seconds of a 13mm diameter 400mW laser 19 interrupte d 10-0 nylon	irradiated for 250 for 250 seconds of a 13mm a 13mm diameter diameter 400mW laser laser 19 15 interrupted d 10-0 nylon nylon sutures	irradiated irradiated a 13mm for 250 for 250 diameter seconds of seconds of 400mW laser a 13mm diameter diameter 400mW 400mW laser laser 19 15 15 interrupte interrupted interrupted d 10-0 10-0 nylon nylon sutures: nylon sutures 10-0 on sutures 9-0 on limbus,

Table 1. Summary of Methods.




Figure 1. Comparison of histopathological results after sealing amniotic membrane over cornea lacerations using laser crosslinking or sutures. The data are the mean values \pm SD of the values measured at three time points (3, 7 and 28 days).




Figure 2. Temperature of the cornea surface during irradiation of RB-impregnated amniotic membrane over a central cornea laceration using $0.25~\text{W/cm}^2$ at 532~nm. (n = 6 / group).




Figure 3. Evaluation of cell viability in iris tissue after sealing amniotic membrane over central cornea lacerations using laser crosslinking. Iris tissue sections were stained with H&E or for LDH activity indicating cell viability by formation of a blue formazan product. Arrows showing the areas of blue formazan.




Figure 4. FFA and ONL thickness measurement of retinas from control eyes and from eyes treated with laser crosslinking to seal amniotic membrane over central cornea lacerations (third arm of study). Images were taken on Day 28 post treatment of (A) control and (B) treated eyes.

(C) ONL thickness measured on H&E sections of retinas in control and treated eyes on Day 1 and Day 28. (n = 6 / group).

- 344 REFERENCES
- 345 Joint Theater Trauma Report, provided by Robert Mazzoli, Evacuation incidents 2002-2012.
- 346 Verter EE, Gisel TE, Yang P, et al. Light-Initiated Bonding of Amniotic Membrane to Cornea,
- 347 IOVS 2011;52(13):9470-9477.
- 348 Irene Kochevar, Final Report: Sealing Penetrating Eye injuries with Photoactivated bonding,
- 349 September 2013.
- 350 Delori F, Webb R, Sliney D. Maximum permissible exposures for ocular safety (ANSI 2000).
- with emphasis on ophthalmic devices. J Opt Soc Am A Opt Image Sci Vis 2007;24:1250-1265.
- 352 Barton K, Budenz DL, Khaw PT, et al. Glaucoma Filtration Surgery using Amniotic Membrane
- 353 Transplantation, IOVS 2001;42(8):1762-1768.
- Tabery HM. Toxic effect of rose bengal dye on the living human corneal epithelium. Acta
- 355 Ophthalmol Scand 1998;76(2):142-145.
- 356 Yang P. Yao M, DeMartelaere SL, et al. Light-activated sutureless closure of wounds in thin
- 357 skin, Lasers Surg Med 2012;44(2):163-167.
- 358 Tsao S, Yao M, Tsao H. Light-activated tissue bonding for excisional wound closure: a split-
- 359 lesion clinical trial, *Br J Dermatol* 2012;166:555-63.
- 360 Proano CE, Azar DT, Mocan MC. Photochemical keratodesmos as an adjunct to sutures for
- bonding penetrating keratoplasty corneal incisions, J Cataract Refract Surg 2004;30:2420-2424.
- 362 Proano CE, Mulroy L, Jones E, et al. Photochemical keratodesmos for bonding corneal incisions,
- 363 Invest Ophthalmol Vis Sci 2004;45:2177-2181.
- Zhu H, Alt C, Webb RH, et al. Corneal Crosslinking With Rose Bengal and Green Light:
- 365 Efficacy and Safety Evaluation, *Cornea* 2016;35(9):1234-1241.

Sherwood ME, Flotte TJ. Improved staining method for determining the extent of thermal
 damage to cells, *Lasers Surg Med* 2007;39:128–131.
 Landry J and Marceau N. Rate-Limiting Events in Hyperthermic Cell Killing, *Radiation Research* 1978;75(3):573-585